Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of Formula (1):



(1)

wherein:

Cy is a group of Formula (2):



(2)

C_{3-7}cycloalkyl or phenyl;

R_1, R_2, R_3, R_4 and R_5 are hydrogen, halogen, hydroxy, amino, trifluoromethyl or nitrile and at least one of R_1, R_2, R_3, R_4 and R_5 is halogen, trifluoromethyl or nitrile;

R_6 is hydrogen, optionally substituted straight-chained or branched C_{1-3}alkyl, amino or hydroxy;

R_7 is hydrogen, optionally substituted straight-chained or branched C_{1-3}alkyl, optionally substituted amino or hydroxy;

R_8 is hydrogen, methyl or ethyl;

R_9 is optionally substituted straight-chained or branched C_{1-6}alkyl, optionally substituted straight-chained or branched C_{2-6}alkenyl, optionally substituted straight-chained or branched C_{2-6}alkynyl, C_{3-7}cycloalkyl or optionally substituted phenyl;

R_{20} is hydrogen or straight-chained or branched C_{1-3}alkyl or R_9 and R_{20} may together form C_{3-7}cycloalkyl;

R_{10} is hydrogen or straight-chained or branched C_{1-3}alkyl;

R_{11} is hydrogen, optionally substituted straight-chained or branched C_{1-3}alkyl, $-CO-N(R_{14})R_{15}$, carboxyl;

R_{12} is hydroxy or $-OR_{16}$;

R_{13} is hydrogen, straight-chained or branched C_{1-6}alkyl, straight-chained or branched C_{2-6}alkenyl, straight-chained or branched C_{2-6}alkynyl or a group of Formula (3):



(3)

R_{14} and R_{15}, which may be the same or different, are <u>each</u> hydrogen, optionally substituted straight-chained or branched C_{1-4}alkyl, C_{3-7}cycloalkyl, straight-chained or branched C_{1-4}alkyloxy, straight-chained or branched C_{1-4}alkylsulfonyl or a heterocyclic ring;

R_{16} is straight-chained C_{1-4}alkyl;

R_{17} is hydrogen or methyl;

R_{18} and R_{19} together form cycloalkyl or C_{3-7}cycloalkenyl;

X is carbonyl or methylene;

Y is carbonyl or methylene;

or a hydrate or pharmaceutically acceptable salt thereof.

2. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2);
or a hydrate or pharmaceutically acceptable salt thereof.

3. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which at least one of R_1, R_2, R_3, R_4 and R_5 is halogen and the others are hydrogen or hydroxy;

or a hydrate or pharmaceutically acceptable salt thereof.

4. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which R_3 is halogen or R_2 and R_3 are the same kind of halogen;
or a hydrate or pharmaceutically acceptable salt thereof.

5. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which R_3 is halogen and R_1, R_2, R_4 and R_5 are hydrogen, or R_2 and R_3 are the same kind of halogen and R_1, R_4 and R_5 are hydrogen;
or a hydrate or pharmaceutically acceptable salt thereof.

6. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which at least one of R_1, R_2, R_3, R_4 and R_5 is trifluoromethyl and the others are hydrogen, halogen or hydroxy;
or a hydrate or pharmaceutically acceptable salt thereof.

7. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which at least one of R_1, R_2, R_3, R_4 and R_5 is nitrile and the others are hydrogen, halogen or hydroxy;
or a hydrate or pharmaceutically acceptable salt thereof.

8. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which R_3 is trifluoromethyl;
or a hydrate or pharmaceutically acceptable salt thereof.

9. (Original) The compound according to claim 1, wherein Cy in Formula (1) is a group of Formula (2) in which R_3 is nitrile;
or a hydrate or pharmaceutically acceptable salt thereof.

Claims 10-12. (Canceled)

13. (Previously Presented) The compound according to claim 1, wherein R_6 in Formula (1) is hydrogen or methyl; or a hydrate or pharmaceutically acceptable salt thereof.

14. (Previously Presented) The compound according to claim 1, wherein R_7 in Formula (1) is hydrogen or optionally substituted amino; or a hydrate or pharmaceutically acceptable salt thereof.

15. (Previously Presented) The compound according to claim 1, wherein R_8 in Formula (1) is hydrogen or methyl; or a hydrate or pharmaceutically acceptable salt thereof.

16. (Previously Presented) The compound according to claim 1, wherein R_9 in Formula (1) is methyl, isopropyl, isobutyl, sec-butyl, tert-butyl, 3-pentyl, neopentyl, cyclohexyl, phenyl, benzyl, para-hydroxybenzyl, cyclohexylmethyl or para-fluorobenzyl;
or a hydrate or pharmaceutically acceptable salt thereof.

17. (Previously Presented) The compound according to claim 1, wherein R_{20} in Formula (1) is hydrogen or methyl; or a hydrate or pharmaceutically acceptable salt thereof.

18. (Previously Presented) The compound according to claim 1, wherein R_{10} in Formula (1) is hydrogen or methyl; or a hydrate or pharmaceutically acceptable salt thereof.

19. (Previously Presented) The compound according to claim 1, wherein R_{11} in Formula (1) is methyl, hydroxymethyl, carbamoylmethyl, methanesulfonylmethyl, ureidemethyl, sulfamoylaminomethyl, methanesulfonylaminomethyl, carbamoyl, ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl, cyclopropylcarbamoyl, tertbutylcarbamoyl, methoxycarbamoyl, methylcarbamoyl, methanesulfonylmethylcarbamoyl, methoxymethylcarbamoyl,; or a hydrate or pharmaceutically acceptable salt thereof.

20. (Previously Presented) The compound according to claim 1, wherein R_{12} in Formula (1) is hydroxy; or a hydrate or pharmaceutically acceptable salt thereof.

21. (Previously Presented) The compound according to claim 1, wherein R_{13} in Formula (1) is isopropyl, tert-butyl (tBu), 1,1-dimethylpropyl or 1,1-dimethyl-2-propenyl; or a hydrate or pharmaceutically acceptable salt thereof.

22. (Previously Presented) The compound according to claim 1, wherein in Formula (1) Cy is a group of Formula (2) in which at least one of R_1, R_2, R_3, R_4 and R_5 is halogen and the others are hydrogen or hydroxy;
R_6 is hydrogen or methyl;
R_7 is hydrogen or optionally substituted amino;
R_8 is hydrogen or methyl;

R_9 is methyl, isopropyl, isobutyl, sec-butyl, tert-butyl, 3-pentyl, neopentyl, cyclohexyl, phenyl, benzyl, para-hydroxybenzyl, para-fluorobenzyl or cyclohexylmethyl;
R_{20} is hydrogen;
R_{10} is hydrogen or methyl;
R_{11} is methyl, hydroxymethyl, carbamoylmethyl, methanesulfonylmethyl, ureidemethyl, sulfamoylaminomethyl, methanesulfonylaminomethyl, carbamoyl, methylcarbamoyl, ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl, cyclopropylcarbamoyl, tert-butylcarbamoyl, , methanesulfonylmethylcarbamoyl, methoxymethylcarbamoyl, or methoxycarbamoyl,;
R_{12} is hydroxy;
R_{13} is isopropyl, tert-butyl (tBu), 1,1-dimethylpropyl or 1,1-dimethyl-2-propenyl;
or a hydrate or pharmaceutically acceptable salt thereof.

23. (Original) The compound according to claim 1 which is selected from the group of compounds consisting of Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Phe(4-Cl)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Phe(3,4-F_2)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Phe(3-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHOMe, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-tertbutyl-4-hydroxyphenyl)-1-(2-pyridylcarbamoyl)ethylamide, N-(2-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methyl-butyrylamino)-3-(3-tBu-4-hydroxyphenyl)propyl)urea, N-(2-(2-(2-amino-3-(4-fluorophenylpropanoyl-N-methylamino)-3-methyl)butyrylamino)-3-(3-tertbutyl-4-hydroxyphenyl)propyl)sulfamide, N-[2-(3-tertbutyl-4-hydroxyphenyl)-1-(methanesulfonylaminomethyl)ethyl]-2-[N-(4-fluorophenylalanyloyl)methylamino]-3-methylbutanamide, 2-((2-

amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-carbamidemethylethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-methanesulfonylmethylethylamide, 2-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methyl-butyrylamino)-3-(3-tBu-4-hydroxyphenyl)propanol, 2-(1-(2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methyl-butyrylamino)-2-(3-tertbutyl-4-hydroxyphenyl)ethyl)-6-methyl-4-pyrimidinone, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,3,4-oxadiazol-2-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,2,4-oxadiazol-5-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-tertbutyl-4-hydroxyphenyl)-1-(thiazol-2-yl)ethylamide, 2-((2-amino-3-(4-fluorophenyl)propionyl)-N-methylamino)-3-methylbutyric acid 2-(3-t-butyl-4-hydroxyphenyl)-1-(1,3,4-triazol-2-yl)ethylamide, Tyr(2-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Tyr(3-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH_2, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH_2, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NH_2, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NH_2, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, N-Me-phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHMe, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH_2, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH_2, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NH_2, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHMe, N-Me-Phe(4-F)-N-Me-Val- N-Et-Tyr(3-tBu)-NHMe, N-Et-

Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHMe, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHtBu, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NHCH_2SO_2CH_3$, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHEt, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHEt, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHEt, Phe(4-F)-N-Me-Val-Tyr(3-tBu)-$NHCH_2OH$, N-Me-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-$NHCH_2OH$, N-Et-Phe(4-F)-N-Me-Val-Tyr(3-tBu)-$NHCH_2OH$, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHEt, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHEt, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)- NHEt, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NHCH_2OH$, N-Me-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NHCH_2OH$, N-Et-Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-$NHCH_2OH$, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHEt, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHEt, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-NHEt, Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-$NHCH_2OH$, N-Me-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-$NHCH_2OH$, N-Et-Phe(4-F)-N-Me-Val-N-Et-Tyr(3-tBu)-$NHCH_2OH$, Phe(4-F)-N-Me-Val-N-Me-Tyr(3-tBu)-NHcPr, and Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHnPr Phe(4-F)-N-Me-Val-Tyr(3-tBu)-NHiPr;
or a hydrate or pharmaceutically acceptable salt thereof.

24. (Previously Presented) A pharmaceutical composition containing an effective amount of the compound according to claim 1 as an active ingredient and an inert pharmaceutically acceptable carrier.

25. (Previously Presented) A motilin receptor antagonist composition containing an effective amount of the compound according to claim 1 and an inert pharmaceutically acceptable carrier.

Claims 26-27. (Cancelled)

28. (Previously Presented) A compound of Formula (4):



(4)

wherein

Cy, R_6, R_8, R_9, R_{20}, R_{10}, R_{12}, R_{13}, X and Y are as defined in claim 1;

R_7' is hydrogen, straight-chained or branched C_{1-3}alkyl optionally having at least one protected substituent, amino optionally having at least one protected substituent or protected hydroxy; and

R_{11}" is hydrogen, optionally substituted straight-chained or branched C_{1-3}alkyl, -CO-N(R_{14})R_{15}, wherein R_{14} and R_{15} are as defined in claim 1, carboxyl, straight-chained or branched C_{1-3}alkyl having a protected amino;
or a hydrate or pharmaceutically acceptable salt thereof.

29. (Previously Presented) A compound of Formula (5):



(5)

wherein:

Cy, R_6, R_8, R_9, R_{20}, R_{10}, R_{12}, R_{13}, X and Y are as defined in claim 1;

R_7" is hydrogen, straight-chained or branched C_{1-3}alkyl optionally having at least one optionally protected

substituent, amino optionally having at least one optionally protected substituent or optionally protected hydroxy; and

R_{11}' is hydrogen, straight-chained or branched C_{1-3}alkyl optionally having at least one protected substituent, -CO-N(R_{14})R_{15} wherein R_{14} and R_{15} are as defined in claim 1, carboxyl

or a hydrate or pharmaceutically acceptable salt thereof.

30. (Currently Amended) A compound of Formula (6):



(6)

wherein:

R_8 is hydrogen, optionally-substituted straight-chained or branched C_{1-3} alkyl, optionally substituted amino, or hydroxy;

R_9, is optionally-substituted straight-chained or branched C_{1-6} alkyl, optionally substituted straight-chained or branched C_{2-6} alkenyl, optionally substituted straight-chained or branched C_{2-6} alkynyl, C_{3-7} cycloalkyl or optionally substituted phenyl;

R_{20} is hydrogen or straight-chained or branched C_{1-3} alkyl; or R_9 and R_{20} may together form C_{3-7} cycloalkyl;

R_{10} is hydrogen or straight-chain or branched C_{1-3} alkyl;

R_{12} is hydroxy or OR_{16};

R_{13} is hydrogen, straight-chained or branched C_{1-6} alkyl, straight-chained or branched C_{2-6} alkenyl, straight-chained or branched C_{2-6} alkynyl or a group of Formula (3)



(3)

Wherein R_{17} is hydrogen or methyl;

R_{18} and R_{19} together form cycloalkenyl or C_{3-7} cycloalkenyl; and

Y is carbonyl or methylene;

P_1 is hydrogen or a protecting group of amine; and

R_{11}''' is hydrogen, optionally substituted straight-chained or branched C_{1-3}alkyl, carboxyl, straight-chained or branched C_{1-3}alkyl having protected amino or an optionally substituted heterocyclic ring, or $-CO-N(R_{14})R_{15}$ wherein R_{14} and R_{15}, which may be the same or different, are hydrogen, optionally substituted straight-chained or branched C_{1-4} alkyl, C_{3-7} cycloalkyl, straight-chained or branched C_{1-4} alkoxy, straight-chained or branched C_{1-4}alkylsulfonyl or a heterocyclic ring~~, carboxyl, straight chained or branched C_{1-3}alkyl having protected amino or an optionally substituted heterocyclic ring~~;

or a hydrate or pharmaceutically acceptable salt thereof.

Claims 31-34. (Canceled)